Pipeline
Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.
Therapy
Product
Field
Indication
Combination
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Partner
oNKord®
Inaleucel (GTA002)
Hematology
AML
N/A
Phase II
medac (EU)
inno.N (Japan and South Korea)
oNKord®
Inaleucel (GTA002)
Hematology
AML
N/A
II
2025
medac (EU)
inno.N (Japan and South Korea)
Inaleucel (GTA002)
Oncology
uLM-CRC*
+/- anti-EGFR mAb
Pre-clinical
oNKord®
Inaleucel (GTA002)
Oncology
uLM-CRC*
+/- anti-EGFR mAb
PRE
TBA
Inaleucel (GTA002)
Auto-immunity
SLE**
anti-CD20 mAb
Pre-clinical
oNKord®
Inaleucel (GTA002)
Auto-immunity
SLE**
anti-CD20 mAb
PRE
viveNK™
CAR-NK (CD19)
Auto-immunity
SLE**
+/- anti-CD20 mAb
Pre-clinical
viveNK™
CAR-NK (CD19)
Auto-immunity
SLE**
+/- anti-CD20 mAb
PRE
TBA
CAR-NK (CD19)
Hematology
B cell Malignancies
+/- anti-CD20 mAb
Pre-clinical
viveNK™
CAR-NK (CD19)
Hematology
B cell Malignancies
+/- anti-CD20 mAb
PRE
CAR NK (CD 19)
TCR-NK (GTA201)
Oncology
TBD
TBD
Development
viveNK™
TCR-NK (GTA201)
Oncology
TBD
TBD
DEV
TBA
Therapy
Phase
Partner
oNKord®
Inaleucel (GTA002)
Hematology
AML
N/A
Phase II
medac (EU)
inno.N (Japan and South Korea)
oNKord®
Inaleucel (GTA002)
Hematology
AML
N/A
II
2025
medac (EU)
inno.N (Japan and South Korea)
Inaleucel (GTA002)
Oncology
uLM-CRC*
+/- anti-EGFR mAb
Pre-clinical
oNKord®
Inaleucel (GTA002)
Oncology
uLM-CRC*
+/- anti-EGFR mAb
PRE
TBA
Inaleucel (GTA002)
Auto-immunity
SLE**
anti-CD20 mAb
Pre-clinical
oNKord®
Inaleucel (GTA002)
Auto-immunity
SLE**
anti-CD20 mAb
PRE
viveNK™
CAR-NK (CD19)
Auto-immunity
SLE**
+/- anti-CD20 mAb
Pre-clinical
viveNK™
CAR-NK (CD19)
Auto-immunity
SLE**
+/- anti-CD20 mAb
PRE
TBA
CAR-NK (CD19)
Hematology
B cell Malignancies
+/- anti-CD20 mAb
Pre-clinical
viveNK™
CAR-NK (CD19)
Hematology
B cell Malignancies
+/- anti-CD20 mAb
PRE
CAR NK (CD 19)
TCR-NK (GTA201)
Oncology
TBD
TBD
Development
viveNK™
TCR-NK (GTA201)
Oncology
TBD
TBD
DEV
TBA